64x Bio, a fledgling synthetic cell and gene therapy manufacturer, brought in $55 million in a series A round of fundraising. The company, which has about 10 employees and was founded in 2020 out of ...
SAN FRANCISCO--(BUSINESS WIRE)--64x Bio announced today that they are emerging from stealth and are describing for the first time their proprietary VectorSelect TM platform and vision for the company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback